Table 3.
Summary estimates of anti-SARS-CoV-2 cross-reactivity.
| SUBGROUPS | Datasets (samples) | Cross-reactivity (95% confidence interval), % | I2 |
|---|---|---|---|
| Antigenic targeta | |||
| Any N | 49 (8,650) | 14 (11-16) | 96.5% |
| Any S | 81 (18,404) | 11 (10-12) | 97.0% |
| S1 | 26 (3,563) | 23 (18-27) | 98.1% |
| RBD | 26 (7.032) | 7 (5-8) | 95.4% |
| Any N +S | 24 (2,679) | 5 (3-8) | 92.2% |
| Type of antibodiesb | |||
| IgG | 112 (23,164) | 11 (9-12) | 96.3% |
| IgM | 18 (2,562) | 13 (9-18) | 96.3% |
| IgG/IgM | 19 (3,128) | 12 (9-16) | 97.3% |
| Malaria burdenc | |||
| High | 126 (25,019) | 14 (12-15) | 96.9% |
| Low/None | 30 (4,004) | 2 (1-2) | 78.8% |
| Dengue burdenc | |||
| High | 118 (22,363) | 12 (10-13) | 96.5% |
| Low/None | 38 (7,560) | 9 (7-10) | 96.1% |
| HIV burdenc | |||
| High | 52 (10,050) | 6 (5-7) | 94.0% |
| Low/None | 91 (17,338) | 13 (11-15) | 96.7% |
Ig, immunoglobulin; N, nucleocapsid; RBD, receptor binding domain; S, spike.
According to chi-square Q test, the differences between subgroups are highly statistically significant (P <0.001) for type of antigenic target, malaria burden, and HIV burden, nominally statistically significant (P <0.05) for dengue burden, and not statistically significant (P >0.05) for type of antibody.
“Any S” includes S (n = 15), S1 (n = 26), S2 (n = 9), RBD (n = 26), receptor binding motif (n = 1), N-terminal domain (n = 4); “N+S” includes N+S (n = 17), N+RBD (n = 2), N+RBD+S (n = 1), N+S2 (n = 2), RBD+N (n = 2); for n = 2 the antigen was unknown.
not shown are IgA (n = 1 dataset), all immunoglobulin subclasses (n = 5 datasets) and unclear (n = 1 dataset).
see Methods for definitions of subgroups.